期刊文献+

转移性肾细胞癌免疫治疗的循证医学

Evidence-Based Medicine of chemoimmunotherapy of metastatic carcionma
下载PDF
导出
摘要 目的针对1例诊断为晚期转移性肾癌患者,借助循证医学的方法进行证据检索和评价,以期找到更合适及有效的治疗方法。方法充分评估患者情况后,提出临床问题,检索Cochrane图书馆(2011年第4期)、Pubmed(1991-2011年)、中国学术期刊全文数据库(1991-2011年)等、万方数据库(1991-2011年)等。查找治疗晚期转移性肾癌有关的系统评价、临床随机对照试验等,并对所获证据进行评价。结果纳入符合要求的的随机对照试验25篇,系统评价或Meta分析23篇,根据所获证据给患者制定治疗方案。结论以高质量证据、结合患者情况制定治疗方案,能明显提高晚期转移性肾癌患者的近期疗效,但远期预后尚需更长时间的随访观察。 Objective In orde to find more appropriate and effective treatment for a patient with metastatic carcionma,we use the methods of evidence-based medicine to retrieve and evaluate literature. Method After a full assessment of the patient,we attempted to get the evidence of methods which are used to treat metastatic carcionma by searching Pubmed(1991-2011) 、 The Cochrane Library(Issue 4,2011) 、CNKI(1991-2011)、WANFANG Datebase(1991-2011). Results A total of 25 randomized controlled trials,23 systematic reviews and meta-analyses were identified.The treatment plan was developed accordingly. Conclusion The individualized treatment plan based on the high quality evidence and patients condition was optimal for the short-term treatment of metastatic carcionma.However,the long-term prognostic benefitsneeded to be confirmed by continuing follow-up.
作者 郑壬平 王伟
出处 《九江学院学报(自然科学版)》 CAS 2012年第3期98-101,111,共5页 Journal of Jiujiang University:Natural Science Edition
关键词 肾细胞癌 转移癌 免疫治疗 生物治疗 循证治疗 renal cell carcinoma metastatic carcionma chemoimmunotherapy biological treatment evidence-Based Treatment
  • 相关文献

参考文献17

  • 1Pitino A, Squillaci S, Spairani C, et al. Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature review. Pathologica, 2011, 103 (5) : 271.
  • 2曹水,高艳,任秀宝.肾癌生物治疗进展[J].实用肿瘤杂志,2010,25(3):237-242. 被引量:1
  • 3Negrier S, Maral J, Drevon M, et al. Long - term follow - up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin -2 in Europe [ J ]. Cancer J Sci Am.2000, 6 (1) : S93.
  • 4Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin -2, recombinant human interferon alfa - 2a, or both in metastatic renal - cell carcinoma. Groupe Francais dlmmunotherapie [J]. N Engl J Med, 1998, 18 (338) : 1272.
  • 5Bukowski R M Cytokine therapy for metastatic renal cell carcinoma [ J ]. Semin Urol Oncol, 2001, 19 (2): 148.
  • 6韩卫军,李允利,王金万,吴建国.白介素-2联合干扰素与单用白介素-2治疗晚期肾癌疗效的Meta分析[J].中国全科医学,2011,14(30):3491-3494. 被引量:5
  • 7Coppin C, Porzsoh F. Immunotherapy for advanced renal cell cancer [ J]. Cochrane Database Syst Rev, 2005, (1) : 1425.
  • 8Fyfe G, isher RI , Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carinoma who received high - dose recombinant interleukin - 2 therapy [ J ]. J Clin Oncol, 1995, (13): 668.
  • 9Fisher RI, Rosenberg SA, Fisher RI, et al. Long - term survival update for high - dose recombi- nant interleukin -2 in patients with renal cell carcinoma [J]. Cancer J Sci Am, 2000, 6: 55.
  • 10Mozter ILl, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: non - Hodgkin~ lymphomas [J]. J Natl Canl Netw, 2010, 8 (3) : 288.

二级参考文献72

  • 1Atkins MB, Bukowski RM, Escudier B J, et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference [ J 3. Cancer,2009,115 ( Suppl 10) :2247 - 2251.
  • 2Uchida K, Miyao N, Masumori N, et al. Recurrence of renal eel1 carcinoma more than 5 years after nephrectomy [ J]. Int J Urol,2002,9( 1 ) : 19 - 23.
  • 3Motzer R.], Bander NH, Nanus DM. Renal cell carcinoma [ J ]. N Engl J Med, 1996,335 ( 12 ) : 865 - 875.
  • 4Waldmann TA. The biology of interleukin-2 and interleukin-15 : implications for cancer therapy and vaccine design [ J ]. Nat Rev Immunol, 2006,6 ( 8 ) : 595 -601.
  • 5Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma wtlo received high-dose recombinant interleukin-2 therapy [ J ]. J Clin Oncol, 1995, 13 ( 3 ) : 688 - 696.
  • 6Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous itffusion rlL-2 in patients with metastatic renal cell carcinoma [ J ]. Br J Cancer, 2004-, 90 (6) : 1156 - 1162.
  • 7Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa- 2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunoth6rapie [J]. N Engl J Med, 1998,338 (18) :1272 - 1278.
  • 8Yang JC, Sherry RM, Stienberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer[J]. J Clin Oncol,2003,21 (16) :3127 - 3132.
  • 9McDermott DF, Regan MM, Clark JI,et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomar [ J]. J Clin Oncol,2005, 23(1) :133 - 141.
  • 10Negrier S, Perol D, Ravaud C, et al. Medroxyprogeste- rone,interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial [ J ]. Cancer, 2007, 110 ( 11 ) :2468 -2477.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部